HOOKIPA Pharma Statistics
Total Valuation
HOOKIPA Pharma has a market cap or net worth of $44.48 million. The enterprise value is -$27.77 million.
Important Dates
The next estimated earnings date is Friday, November 15, 2024, before market open.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HOOKIPA Pharma has 12.05 million shares outstanding. The number of shares has increased by 58.15% in one year.
| Current Share Class | 9.66M |
| Shares Outstanding | 12.05M |
| Shares Change (YoY) | +58.15% |
| Shares Change (QoQ) | -0.47% |
| Owned by Insiders (%) | 0.13% |
| Owned by Institutions (%) | 23.36% |
| Float | 6.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.84 |
| Forward PS | n/a |
| PB Ratio | 0.52 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.86, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.86 |
| Quick Ratio | 3.58 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -508.28 |
Financial Efficiency
Return on equity (ROE) is -48.99% and return on invested capital (ROIC) is -30.61%.
| Return on Equity (ROE) | -48.99% |
| Return on Assets (ROA) | -20.10% |
| Return on Capital (ROIC) | -30.61% |
| Revenue Per Employee | $291,413 |
| Profits Per Employee | -$271,486 |
| Employee Count | 179 |
| Asset Turnover | 0.33 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HOOKIPA Pharma has paid $163,000 in taxes.
| Income Tax | 163,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.34% in the last 52 weeks. The beta is 0.83, so HOOKIPA Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -20.34% |
| 50-Day Moving Average | 4.28 |
| 200-Day Moving Average | 6.31 |
| Relative Strength Index (RSI) | 38.82 |
| Average Volume (20 Days) | 46,213 |
Short Selling Information
The latest short interest is 26,040, so 0.22% of the outstanding shares have been sold short.
| Short Interest | 26,040 |
| Short Previous Month | 35,190 |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.37% |
| Short Ratio (days to cover) | 0.84 |
Income Statement
In the last 12 months, HOOKIPA Pharma had revenue of $52.16 million and -$48.60 million in losses. Loss per share was -$4.11.
| Revenue | 52.16M |
| Gross Profit | -32.37M |
| Operating Income | -50.83M |
| Pretax Income | -48.43M |
| Net Income | -48.60M |
| EBITDA | -47.71M |
| EBIT | -50.83M |
| Loss Per Share | -$4.11 |
Full Income StatementBalance Sheet
The company has $77.15 million in cash and $4.90 million in debt, giving a net cash position of $72.25 million or $5.99 per share.
| Cash & Cash Equivalents | 77.15M |
| Total Debt | 4.90M |
| Net Cash | 72.25M |
| Net Cash Per Share | $5.99 |
| Equity (Book Value) | 86.06M |
| Book Value Per Share | 7.14 |
| Working Capital | 79.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$73.88 million and capital expenditures -$3.60 million, giving a free cash flow of -$77.48 million.
| Operating Cash Flow | -73.88M |
| Capital Expenditures | -3.60M |
| Free Cash Flow | -77.48M |
| FCF Per Share | -$6.43 |
Full Cash Flow StatementMargins
Gross margin is -62.05%, with operating and profit margins of -97.44% and -93.16%.
| Gross Margin | -62.05% |
| Operating Margin | -97.44% |
| Pretax Margin | -92.85% |
| Profit Margin | -93.16% |
| EBITDA Margin | -91.46% |
| EBIT Margin | -97.44% |
| FCF Margin | -148.53% |
Dividends & Yields
HOOKIPA Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.15% |
| Shareholder Yield | -58.15% |
| Earnings Yield | -109.25% |
| FCF Yield | -174.18% |
Analyst Forecast
The average price target for HOOKIPA Pharma is $39.25, which is 963.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $39.25 |
| Price Target Difference | 963.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 58.88% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 10, 2024. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Jul 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
HOOKIPA Pharma has an Altman Z-Score of -3.13 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.13 |
| Piotroski F-Score | 3 |